Vivos Therapeutics, Inc. (VVOS) rose 8.83 percent to $3.30 on Thursday after the European Journal of Pediatrics published favorable results from a multicenter clinical trial supporting the company's patented Daytime-Nighttime Appliance for treating obstructive sleep apnea in children.
The stock opened at $3.54 and traded between $3.26 and $3.89 on volume of 1.29 million shares, significantly above its average of 125,000 on the Nasdaq. The move brought the stock closer to its 52-week high of $6.28, up from a previous close of $3.04. Its 52-week low stands at $1.97.
The study highlighted that 79 percent of participants showed improvement, with 17 percent seeing complete resolution of symptoms and no safety concerns reported.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.